Ranbaxy reports Q1 Drug Store News Ranbaxy attributed its sales boost to the launch of generic Lipitor (atorvastatin), as well as sales of generic Caduet (amlodipine and atorvastatin). "The focus on key products and markets, while maintaining emphasis on further strengthening quality ...

Business Line Ranbaxy: Positives priced in Business Standard (blog) Sales in the US surged a huge 159 per cent to $410 million in the March quarter, of which Lipitor (a cholesterol lowering drug) and Caduet (a drug prescribed to treat conditions that affect the heart and blood vessels) contributed around $316 million. Short Takes - Pharma galore

Ranbaxy Labs - Q1CY12 Result update Estimate change - Centrum Equity Bulls RLL reported 71%YoY growth in revenues due to FTF opportunities of generic Lipitor and Caduet in the US market. EBIDTA margin improved by 760bps YoY from 19.2% to 26.8% due to high margin FTF opportunities. The company's other income grew by 98%YoY ...

India Markets Thursday Wrap-Up: Volatility Plagues Indian Bourses Seeking Alpha This was largely led by healthy growth in base business sales and continued sale of 2 exclusivity products notably Atorvastatin (Lipitor) and Amlodipine+Atorvastatin ( Caduet ). Operating margins improved substantially by 7.6% to 26.8% due to reduction ...

Ranbaxy Q1 numbers positively surprised everybody: Surajit Pal, Elara Capital Economic Times So out of $736 million, Lipitor plus Caduet put together in US is $330 mn. We can assume another 20% to the max and the most optimistic scenario of Lipitor sale seems other geography including Europe, Asia and Australia. ET Now: After the performance ...

Business Today Lipitor delivers impressive margins for Ranbaxy Hindu Business Line Ranbaxy Laboratories' sales growth and high profit margins were helped mainly by sales of Lipitor and Caduet on an exclusive basis in the US. Ranbaxy's US sales stood at $416 million vis-Ã -vis $170 million last year. It was the key driver behind the ... Ranbaxy First-Quarter Profit Up Over Fourfold, Shares Jump Ranbaxy Q1 net jumps 310%; to set up new plant in Nigeria Ranbaxy earnings rocket thanks to generic Lipitor

Wall Street Journal Ranbaxy's Net Profit Soars Wall Street Journal The introduction of the much-awaited Lipitor generic in November, followed by authorized sales of a generic version of Pfizer's Caduet blood-pressure pill, contributed in a big way to Ranbaxy's sales and earnings. Consolidated net profit in the quarter ... Ranbaxy Q1 PAT seen up 34% at Rs 408 cr

Pfizer's Declining R&D: Count Me Out Seeking Alpha In 2011 alone Pfizer lost exclusivity on Vfend ($747 million in 2011 sales worldwide), Xalatan ($1.25 billion), Caduet ($528 million), Protonix, Aromasin ($361 million), and of course Lipitor ($9.6 billion). In 2012 Pfizer will lose exclusivity on ...